Importantly, serum gelsolin, particularly together with lumican, was proposed as a highly sensitive combined biomarker for distinguishing pancreatic cancer and pancreatitis (at 95% specificity gelsolin-lumican reached 80% sensitivity) [72]. Here, LUM is linked to pancreatic neoplasm.